Journal Watch · Cell Reports Medicine · 2026

Role of dopamine in the development of impaired counterregulation and impaired awareness of hypoglycemia.

These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

Macon E, Devore MH, Vieira de Abreu A et al.Cell Reports Medicine3 min readPharma relevance 60/100

DOI: 10.1016/j.xcrm.2026.102710PMID: 41903547Study type: research study

TL;DR

These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

Key findings

  • Finally, dopaminergic modulation of the ventral tegmental area (VTA) induces reciprocal changes in CRR to hypoglycemia with matching changes in VTA dopaminergic gene expression.
  • These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

What they did

A drug screen identifies the dopamine antagonist, metoclopramide (MET), that prevents the development of HAAF. Additionally, following the induction of HAAF, MET restores normal awareness and CRRs. Conversely, the dopamine receptor agonist (bromocriptine), when administered centrally, induces HAAF.

Full abstract (original)

Background: For people with diabetes, the syndrome of hypoglycemia-associated autonomic failure (HAAF) is composed of a blunted counterregulatory response (CRR) and impaired awareness of hypoglycemia (IAH). The objective herein is to identify a drug that might correct these components of HAAF. A rodent model of HAAF was developed to induce both impaired CRR and IAH (blunted food intake response to hypoglycemia).

What they did: A drug screen identifies the dopamine antagonist, metoclopramide (MET), that prevents the development of HAAF. Additionally, following the induction of HAAF, MET restores normal awareness and CRRs. Conversely, the dopamine receptor agonist (bromocriptine), when administered centrally, induces HAAF.

Results & conclusions: Finally, dopaminergic modulation of the ventral tegmental area (VTA) induces reciprocal changes in CRR to hypoglycemia with matching changes in VTA dopaminergic gene expression. These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

Abstract © the authors / Cell Reports Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.xcrm.2026.102710 · PubMed 41903547.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cell Reports Medicine study find?

These data identify dopamine signaling as a critical mediator of HAAF and dopamine antagonism as a potential treatment strategy.

What type of study is this?

It is a research study, published in Cell Reports Medicine in 2026. A drug screen identifies the dopamine antagonist, metoclopramide (MET), that prevents the development of HAAF.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.xcrm.2026.102710. PubMed ID: 41903547. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Macon E, Devore MH, Vieira de Abreu A et al.. Role of dopamine in the development of impaired counterregulation and impaired awareness of hypoglycemia.. Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.102710.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/role-of-dopamine-in-the-development-of-impaired-counterregulation-and-im-102710/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides